Dipexium Pharmaceuticals (NASDAQ:DPRX) said that the European Patent Office has issued a new Locilex patent in the EU.
The patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide formulated as a topical cream, and the use of Locilex as a method of treating skin or wound infections. The issued patent has an expiry date in June 2033.
“This constitutes the first patent granted by the European Union, the second largest pharmaceuticals market in the world,” David Luci, president and CEO, said in a statement. “This is an important building block for our commercialization strategy for Locilex in Europe.”
Dipexium now has issued patents for Locilex in the U.S., EU, and Japan, the three largest pharmaceuticals markets in the world, as well as Australia and New Zealand. In addition, Dipexium has obtained notice of allowance for patents in Hong Kong and Korea. “We anticipate the issuance of additional patents for Locilex in other major international markets throughout 2016 and 2017,” he added.
